Sheela Upadhyaya | Life Science Advisor in Rare Diseases
Openflex Ltd

Day 2 - Wednesday 29 October @ 12:00

Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Diseases

This panel will explore the practical implications that industry and patient organizations need to consider when engaging given the evolving landscape of HTA in Europe

Patrick Hopkinson, Independent HTA Expert, Independent HTA Expert

×

Patrick Hopkinson / Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Diseases

Patrick Hopkinson, Independent HTA Expert,
Independent HTA Expert

Patrick Hopkinson is a Global Market Access/ HEOR expert with over 25 years experience. He is an independent consultant, founder and managing director of PHTA Consulting.  He is a senior leader in the life sciences industry with extensive expertise gained from working across multiple functions in...

CloseMore

Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

×

Alexander Natz / Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Diseases

Alexander Natz, Secretary General,
EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law...

CloseMore

Sheela Upadhyaya, Life Science Advisor in Rare Diseases, Openflex Ltd

Jan Mol, Patient Advocate, Hematon

×

Jan Mol / Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Diseases

Jan Mol, Patient Advocate,
Hematon

CV: JAN A. MOL, PhD (www.uu.nl/staff/jamol) UNIVERSITY OF UTRECHT, LYMPHOMA COALITION Jan Mol is a retired cell biologist of Utrecht University and patient advocate for people with various forms of blood cancer. Jan Mol graduated from Wageningen University (Molecular Sciences) and did his PhD...

CloseMore

Moderator: Veronica Lopez Gousset, DrPH candidate, Harvard T.H. Chan School of Public Health

×

Veronica Lopez Gousset / Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Diseases

Veronica Lopez Gousset, DrPH candidate,
Harvard T.H. Chan School of Public Health

Veronica Lopez Gousset, MPH has over 10 years of experience driving multi-stakeholder initiatives toward patient-centered healthcare change. She works with the patient community to better voice their needs and challenges, with health technology assessment bodies as the gateway to services and...

CloseMore

Day 2 - Wednesday 29 October @ 14:25

How do you assess evidence in Rare? The work of HTAi RDIG

Alicia Granados, Global Head Scientific Advocacy and Insights, Sanofi

×

Alicia Granados / How do you assess evidence in Rare? The work of HTAi RDIG

Alicia Granados, Global Head Scientific Advocacy and Insights,
Sanofi

Alicia Granados is a highly accomplished leader in the field of rare diseases, currently serving as the Head of Global Rare Diseases Medical Scientific Advocacy at Sanofi, where previously she headed its global HTA strategy .With almost 15 years of experience in the pharmaceutical industry, Alicia...

CloseMore

Karen Facey, Chair HTAi Rare Disease Interest Group, University of Edinburgh

×

Karen Facey / How do you assess evidence in Rare? The work of HTAi RDIG

Karen Facey, Chair HTAi Rare Disease Interest Group,
University of Edinburgh

Karen Facey PhD CStat worked in senior statistical roles in the pharmaceutical industry and medicines regulation, before becoming CEO of the first national health technology asssessment (HTA) agency in Scotland in 2000. For the past 20 years Karen has had a portfolio career working internationally...

CloseMore

Sheela Upadhyaya, Life Science Advisor in Rare Diseases, Openflex Ltd

Session led by:

×

Anne-Sophie Chalandon / How do you assess evidence in Rare? The work of HTAi RDIG

Anne-Sophie Chalandon, Head of Global Public Affairs, Rare Diseases and CGT Policies,
SANOFI

  Anne-Sophie Chalandon works to further enhance Sanofi’s external engagement and policy shaping efforts with rare disease community. She brought a solid experience and demonstrated successes in patient advocacy and policy shaping in the rare disease space. Anne-Sophie is a major in genetic and...

CloseMore